Merus (NASDAQ:MRUS) Receives Average Recommendation of “Buy” from Brokerages

Shares of Merus (NASDAQ:MRUS) have been given a consensus rating of “Buy” by the sixteen analysts that are currently covering the company, MarketBeat reports. Fourteen analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $85.92.

A number of research firms have commented on MRUS. Needham & Company LLC reaffirmed a “buy” rating and set a $85.00 price target on shares of Merus in a research report on Monday, December 9th. The Goldman Sachs Group assumed coverage on Merus in a research report on Thursday, November 21st. They issued a “buy” rating and a $73.00 target price for the company. UBS Group assumed coverage on Merus in a research report on Thursday, October 24th. They issued a “buy” rating and a $72.00 target price for the company. Wells Fargo & Company assumed coverage on Merus in a research report on Friday, February 7th. They issued an “overweight” rating and a $91.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $85.00 target price on shares of Merus in a research report on Monday, December 2nd.

Merus Price Performance

MRUS opened at $47.63 on Friday. The business has a 50 day simple moving average of $41.63 and a two-hundred day simple moving average of $46.97. The firm has a market capitalization of $3.26 billion, a price-to-earnings ratio of -12.06 and a beta of 1.11. Merus has a one year low of $37.77 and a one year high of $61.61.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in MRUS. nVerses Capital LLC raised its stake in Merus by 750.0% during the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 1,500 shares during the last quarter. Moody Aldrich Partners LLC bought a new stake in shares of Merus in the 3rd quarter worth $1,527,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Merus by 24.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 489 shares in the last quarter. Novo Holdings A S increased its holdings in shares of Merus by 3.7% in the 3rd quarter. Novo Holdings A S now owns 700,000 shares of the biotechnology company’s stock worth $34,972,000 after purchasing an additional 25,000 shares in the last quarter. Finally, abrdn plc bought a new stake in shares of Merus in the 3rd quarter worth $4,357,000. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.